<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181012</url>
  </required_header>
  <id_info>
    <org_study_id>LIDODOULABDO</org_study_id>
    <secondary_id>CSET 2003/1054</secondary_id>
    <nct_id>NCT00181012</nct_id>
  </id_info>
  <brief_title>Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics</brief_title>
  <official_title>Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics: Efficacy Study in Adults and Children. Randomized Prospective Study With Direct Individual Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain
      resistant to morphinics. It is an efficacy study in adults and children and a randomized
      prospective study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine prospectively the lidocaine efficacy in 2 types of patient populations with cancer (group A: children from 6 to 14 years old and group B: adults from 15 to 70 years old)</measure>
    <time_frame>continuous intravenous perfusion for 6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To confirm the tolerance of the lidocaine</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from cancer of any type, at any stage, hospitalized at the Institut
             Gustave Roussy

          -  Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults)

          -  Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to
             peritoneal carcinosis

          -  Pain resistant to morphinic treatment

        Exclusion Criteria:

          -  Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction
             (MI) of less than 3 months

          -  Neurological: non-controlled epilepsy, encephalopathy, or dementia

          -  Severe hepatic insufficiency

          -  Severe renal insufficiency

          -  Respiratory insufficiency

          -  Patients having surgery or in postoperative period

          -  Known deficit in G6PD, alanine exposure, or sulphamide treatment

          -  Porphyria

          -  Weight &gt; 80 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Poulain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Poulain, MD</last_name>
    <phone>33 1 42 11 40 53</phone>
    <email>poulain@igr.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Poulain, MD</last_name>
      <phone>33 1 42 11 40 53</phone>
      <email>poulain@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 18, 2007</last_update_submitted>
  <last_update_submitted_qc>September 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2007</last_update_posted>
  <keyword>Cancer Related Visceral Pain Resistant to Morphinics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Visceral Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

